Bruker Corp Files 10-K for Fiscal Year Ended December 31, 2023

TL;DR

<b>Bruker Corp has filed its 2023 annual 10-K report detailing its financial performance and corporate information.</b>

AI Summary

BRUKER CORP (BRKRP) filed a Annual Report (10-K) with the SEC on February 29, 2024. Bruker Corp filed its annual 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Delaware and headquartered in Billerica, MA. Bruker Corp was formerly known as Bruker Biosciences Corp and Bruker Daltonics Inc. The SIC code for Bruker Corp is 3826, indicating Laboratory Analytical Instruments. The filing was made on February 29, 2024.

Why It Matters

For investors and stakeholders tracking BRUKER CORP, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Bruker Corp's financial health, operational performance, and strategic direction for the fiscal year 2023, crucial for investors and stakeholders to assess the company's current standing and future prospects. The detailed financial data and risk factors disclosed in this report are essential for making informed investment decisions and understanding potential challenges the company may face.

Risk Assessment

Risk Level: medium — BRUKER CORP shows moderate risk based on this filing. The company operates in the Laboratory Analytical Instruments sector, which can be subject to market fluctuations and technological advancements, as indicated by its SIC code 3826.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to assess Bruker Corp's performance and identify potential investment opportunities or risks.

Key Numbers

• 20231231 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
• 20240229 — Filing Date (FILED AS OF DATE)
• 000-30833 — SEC File Number (SEC FILE NUMBER)
• 24703372 — Film Number (FILM NUMBER)

Key Players & Entities

• BRUKER CORP (company) — FILER
• 0001109354 (company) — CENTRAL INDEX KEY
• 3826 (company) — STANDARD INDUSTRIAL CLASSIFICATION
• DE (company) — STATE OF INCORPORATION
• BILLERICA (company) — CITY
• MA (company) — STATE
• BRUKER BIOSCIENCES CORP (company) — FORMER COMPANY
• BRUKER DALTONICS INC (company) — FORMER COMPANY

FAQ

Industry Context

Bruker Corp operates within the laboratory analytical instruments industry, providing scientific instruments and analytical solutions for research and diagnostics.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to investors.

What Investors Should Do

1. Analyze the financial statements for revenue trends, profitability, and cash flow.
2. Review any disclosed risk factors to understand potential challenges and their impact.
3. Compare key financial metrics to previous periods to identify performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-02-29: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing analyzed for the fiscal year 2023. Previous filings would provide comparative data.

Filing Documents

• brkr-20231231.htm (10-K) — 5448KB
• brkr-ex10_29.htm (EX-10.29) — 149KB
• brkr-ex10_30.htm (EX-10.30) — 702KB
• brkr-ex10_31.htm (EX-10.31) — 494KB
• brkr-ex21_1.htm (EX-21.1) — 104KB
• brkr-ex23_1.htm (EX-23.1) — 4KB
• brkr-ex31_1.htm (EX-31.1) — 15KB
• brkr-ex31_2.htm (EX-31.2) — 16KB
• brkr-ex32_1.htm (EX-32.1) — 15KB
• brkr-ex97_1.htm (EX-97.1) — 70KB
• img217358612_0.jpg (GRAPHIC) — 47KB
• 0000950170-24-023038.txt (&nbsp;) — 27628KB
• brkr-20231231.xsd (EX-101.SCH) — 2983KB
• brkr-20231231_htm.xml (XML) — 6251KB

Business

Business 3 Item 1A

Risk Factors

Risk Factors 18 Item 1B Unresolved Staff Comments 32 Item 1C Cybersecurity 33 Item 2

Properties

Properties 34 Item 3

Legal Proceedings

Legal Proceedings 35 Item 4 Mine Safety Disclosures 35 Part II Item 5 Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 36 Item 6 Reserved 37 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 49 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 51 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 109 Item 9A

Controls and Procedures

Controls and Procedures 109 Item 9B Other Information 109 Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 110 Part III Item 10 Directors, Executive Officers and Corporate Governance 111 Item 11

Executive Compensation

Executive Compensation 111 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 111 Item 13 Certain Relationships and Related Transactions, and Director Independence 111 Item 14 Principal Accountant Fees and Services 111 Part IV Item 15 Exhibits, Financial Statements and Schedules 112 Item 16 Form 10-K Summary 115

Signatures

Signatures 116 1 Any statements contained in this Annual Report on Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Without limiting the foregoing, the words "believe," "anticipate," "plan," "expect," "seek," "may," "will," "intend," "estimate," "should," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding: the impact of supply chain challenges on our business and operations; expectations regarding the global economy, inflation, the potential for recession and geopolitical tensions and any resulting sanctions, or wars; our intentions regarding our intellectual property; the impact of government contracts and government regulation; our working capital requirements and sufficiency of cash; our competition; the seasonality of our business; the sufficiency of our facilities; our employee relations; the impact of legal or intellectual property proceedings; the impact of changes to tax and accounting rules and changes in law; our anticipated tax rate; our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures; the impact of foreign currency exchange rates and changes in commodity prices; the impact of our restructuring initiatives; our ability to successfully complete significant acquisitions on a timely basis, including the receipt of required regulatory approvals and the satisfaction of required conditions to the completion of prospective acquisitions; the level and impact of our M&A activity and our ability to integrate acquired companies; our expectations regarding backlog and revenue; and any other statements that address events or development

BUSINESS

ITEM 1 BUSINESS Our Business We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Our technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography, triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy, and infrared and Raman molecular spectroscopy technologies. Our product portfolio also includes testing solutions used in microbiology and infectious disease diagnostics, including our MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips and fluorescence-based polymerase chain reaction (PCR) technology for selected infectious disease applications. We develop, manufacture and distribute a range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE detection. We also develop, manufacture and market low temperature superconducting materials and devices based primarily on metallic low temperature superconductors. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, North America and Southeast Asia, and have sales offices located throughout the world. Business Segments We have four report

View Full Filing

View this 10-K filing on SEC EDGAR